Hydroxyprogesterone caproate 快速询单 CAS No.:630-56-8 分子式:C27H40O4 分子量:428.6041 别名:己酸羟孕酮;长效黄体酮;己酸孕酮;17α-羟基孕酮己酸盐;17alpha-Hydroxyprogesterone Caproate 17α-羟基孕酮己酸盐;己酸孕酮 USP标准品;己酸孕酮(长效黄体酮);17α-羟基孕甾-4-烯-3,20-二酮己酸酯;羟孕酮己酸酯...
Preterm birth is defined as the birth of an infant between 20 weeks 0 days and 36 weeks 6 days ofgestation. Deliveries that are early by five weeks or more are the leading cause of infant morbidity and mortality in the United States. Progesterone is known to have an inhibitory effect o...
英文名称17a-Hydroxyprogesterone caproate 生化机理具有抗癌和抗炎特性的抗雌激素。作用于孕激素受体。 储存温度2-8°C储存 运输条件冰袋运输 作用类型激动剂 作用机制孕酮受体激动剂 备注如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的...
CAS号:630-56-8 MDL号: 分子式:C27H40O4 分子量:428.61 g/mol COAMSDS大包装询价 库存状态为分装好的现货产品(1.2.3...等具体数量),每日16:00前订单当天发出; 库存状态为未分装好的现货产品(显示 “现货” 字样),每日15:00前的订单1-3个工作日发出; 若小...
Perfusion of 17-alpha-hydroxyprogesterone caproate (17HPC) via the maternal circuit of a dually perfused human placental lobule resulted in the extensive formation of 2 metabolites. On the other hand, human placental microsomes biotransformed 17HPC into 5 monohydroxylated metabolites, which did not co...
List of Drug Master Files (DMF) of 17alpha-Hydroxyprogesterone n-caproate Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website
On October 29, 2019, a US Food and Drug Administration advisory committee voted 9 vs 7 to withdraw interim accelerated approval of 17-alpha hydroxyprogesterone caproate for preventing recurrent preterm birth because the called for a confirmatory trial, known as the Prevention of Preterm Birth in ...
The aim was to determine whether progesterone (P4) or 17-alpha-hydroxyprogesterone caproate (17P) directly inhibit human uterine contractility in vitro and thereby clarify their mechanisms of action. Myometrial tissues were suspended in organ chambers and exposed for 2 to 20 hours to varying concen...
Delivery before 35 weeks occurred in 11% (N=122/1130) of women given 17-alpha hydroxyprogesterone caproate compared to 11.5% (N=66/578) given placebo (RR 0.95; 95%CI: 0.71-1.26, P=0.72).9 Similarly, the co-primary outcome neonatal composite index occurred in 5.6% (N=61/1093) of ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-2385. PubMedGoogle ScholarCrossref 2. Armstrong J. Unintended consequences–the cost of preventing preterm births after FDA approval of a branded version of 17OHP. N Engl J ...